Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason E Stout

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
Open Forum Infectious Diseases|August 12, 2022
Clinical Features and Treatment Outcomes of Pulmonary <i>Mycobacterium avium-intracellulare</i> Complex With and Without CoinfectionsGrace Wang, Jack T Stapleton, Arthur W Baker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2020
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineCharles L Daley, Jonathan M Iaccarino, Christoph Lange, et al.
The European Respiratory Journal|July 9, 2020
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guidelineCharles L Daley, Jonathan M Iaccarino, Christoph Lange, et al.
The European Respiratory Journal|March 24, 2018
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statementJakko van Ingen, Timothy Aksamit, Claire Andrejak, et al.
Plos Biology|September 9, 2025
Cathepsin Z is a conserved susceptibility factor underlying tuberculosis severityRachel K Meade, Oyindamola O Adefisayo, Marco T P Gontijo, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Cathepsin Z is a conserved susceptibility factor underlying tuberculosis severityRachel K Meade, Oyindamola O Adefisayo, Marco T P Gontijo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 13, 2025
Epidemiology of Healthcare Facility-Associated Nontuberculous Mycobacteria From 2012 Through 2020 in a 10-Hospital Network in the United StatesArthur W Baker, Ricardo M La Hoz, Judith A Anesi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 22, 2020
Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial DiseaseGetahun Abate, Jack T Stapleton, Nadine Rouphael, et al.
Contemporary Clinical Trials|September 7, 2025
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB designEkaterina V Kurbatova, Kelly E Dooley, Wendy Carr, et al.
Medrxiv : the Preprint Server for Health Sciences|January 19, 2022
Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysisLeon Di Stefano, Elizabeth L Ogburn, Malathi Ram, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Open Forum Infectious Diseases|August 12, 2022
Clinical Features and Treatment Outcomes of Pulmonary <i>Mycobacterium avium-intracellulare</i> Complex With and Without CoinfectionsGrace Wang, Jack T Stapleton, Arthur W Baker, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2020
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineCharles L Daley, Jonathan M Iaccarino, Christoph Lange, et al.
The European Respiratory Journal|July 9, 2020
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guidelineCharles L Daley, Jonathan M Iaccarino, Christoph Lange, et al.
The European Respiratory Journal|March 24, 2018
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statementJakko van Ingen, Timothy Aksamit, Claire Andrejak, et al.
Plos Biology|September 9, 2025
Cathepsin Z is a conserved susceptibility factor underlying tuberculosis severityRachel K Meade, Oyindamola O Adefisayo, Marco T P Gontijo, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Cathepsin Z is a conserved susceptibility factor underlying tuberculosis severityRachel K Meade, Oyindamola O Adefisayo, Marco T P Gontijo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 13, 2025
Epidemiology of Healthcare Facility-Associated Nontuberculous Mycobacteria From 2012 Through 2020 in a 10-Hospital Network in the United StatesArthur W Baker, Ricardo M La Hoz, Judith A Anesi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 22, 2020
Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial DiseaseGetahun Abate, Jack T Stapleton, Nadine Rouphael, et al.
Contemporary Clinical Trials|September 7, 2025
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB designEkaterina V Kurbatova, Kelly E Dooley, Wendy Carr, et al.
Medrxiv : the Preprint Server for Health Sciences|January 19, 2022
Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysisLeon Di Stefano, Elizabeth L Ogburn, Malathi Ram, et al.
Pageof 14